Vigonvita Life Sciences Co., Ltd. (HKG:2630)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Pharmaceuticals	102.10M	11.83M	199.65M
Pharmaceuticals Growth	762.88%	-94.07%	-
Total	102.10M	11.83M	199.65M
Total Growth	762.88%	-94.07%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
People's Republic of China (PRC)	101.94M	11.79M	198.98M
People's Republic of China (PRC) Growth	764.63%	-94.07%	-
Uzbekistan	156.00K	42.00K	674.00K
Uzbekistan Growth	271.43%	-93.77%	-
Total	102.10M	11.83M	199.65M
Total Growth	762.88%	-94.07%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every year for this company.

Update frequency:

Yearly

Last checked:

Jun 22, 2026

Data Sources Report a data error